Immunoreactive Calcitonin in Human Cerebrospinal Fluid∗*

Pavlinac, Dennis; Lenhard, Linda; Parthemore, Jacqueline G.; Deftos, Leonard J.

doi:10.1210/jcem-50-4-717

Cited by 57 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoreactive CT has been detected in the hypothalamus of man and of thyroidectomized monkeys (12,22), and evidence has been reported for the presence of hypocalcemic factors in the hypothalamus of guinea pigs and cattle (23,24). Immunoreactive CT-like components have been demonstrated on gel filtration analysis of human cerebrospinal fluid, pheochromocytoma, and porcine pituitaries (5-7, 9, 12, 14-16, 24).…”

Section: Discussionmentioning

confidence: 98%

“…Indeed, immunoreactive CT has been demonstrated in the nervous system ofa primitive ascidian, the sea-squirt, primitive chordates, the lizard, and the pigeon, as well as in the pituitary and the adrenal gland (4)(5)(6)(7)(8)(9)(10)(11). Among human neural tissues, immunoreactive CT has been detected in the cerebrospinal fluid and in extracts of the hypothalamus, pheochromocytoma, and a mucosal neuroma (12)(13)(14)(15)(16).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Fischer¹,

Tobler²,

Kaufmann³

et al. 1981

Proc. Natl. Acad. Sci. U.S.A.

174

View full text Add to dashboard Cite

Immunoreactive calcitonin (CT), indistinguishable from human CT-(1-32) and its sulfoxide, has been identified in extracts of the hypothalamus, the pituitary, and the thyroid obtained from human subjects at autopsy. CT concentrations were highest in a region encompassing the posterior hypothalamus, the median eminence, and the pituitary; intermediate in the substantia nigra, the anterior hypothalamus, the globus pallidus, and the inferior colliculus; and low in the caudate nucleus, the hippocampus, the amygdala, and the cerebral and cerebellar cortices. Specific CT binding measured with "MI-labeled salmon CT was high-

show abstract

Section: Discussionmentioning

confidence: 98%

mentioning

confidence: 99%

Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Fischer¹,

Tobler²,

Kaufmann³

et al. 1981

Proc. Natl. Acad. Sci. U.S.A.

174

View full text Add to dashboard Cite

show abstract

“…Calcitonin was first reported in human CSF by Pavlinac et al [46]. This study was prompted by the reports of calcito nin-like immunoreactivity in the pituitary gland of several species, including man [15][16][17]41].…”

Section: Calcitoninmentioning

confidence: 99%

Adenohypophyseal Hormones in the CSF

Lenhard¹,

Deftos²

1982

Neuroendocrinology

View full text Add to dashboard Cite

The presence of adenohypophyseal hormones in human cerebrospinal fluid (CSF) has been firmly established by radioimmunoassay procedures. The hormones can originate from the adenohypophysis itself and from brain, as well as from peripheral sites of production. These peptide hormones enter the CSF through the choroid plexus or by direct secretion. The hormones entering by direct secretion into the CSF have a higher CSF-blood ratio than the hormones entering through the choroid plexus. Elevated CSF levels of adenohypophyseal hormones are most likely to occur in the presence of hormone-producing pituitary tumors with suprasellar extension. Although the CSF concentrations of adenohypophyseal hormones may merely reflect their blood concentrations, it is more likely that these hormones also have paracrine as well as endocrine effects.

show abstract

“…[3][4][5][6][7] Salmon calcitonin has been used by various routes in the management of chronic pain associated with a bone disease or bone cancer. 8 It has also been used as an adjuvant to local anesthetic in subarachnoid block to increase the efficacy of block, duration of postoperative analgesia and reduce postoperative analgesic requirements.…”

mentioning

confidence: 99%

Efficacy and safety of two different doses of intrathecal calcitonin, a randomized controlled study

2018

View full text Add to dashboard Cite

Background: Adjuvants play an important role in enhancing the quality of anesthesia and also in reducing the requirement of primary anesthetic and its related adverse events. Calcitonin is one such adjuvant. But there is still uncertainty regarding the appropriate dose of calcitonin to achieve maximum analgesic efficacy and safety. The current study is conducted to add to the existing evidence on the subject and was aimed to compare the efficacy and safety of two different doses of calcitonin as an adjuvant in patients undergoing spinal anesthesia.Methods: A prospective randomized controlled double-blind trial was conducted in the Department of Anesthesiology and Intensive Care, Sir Sunderlal Hospital, Banaras Hindu University from May 2006 to May 2007. A total of 80 participants aged between 18 to 60 years, with ASA I and II physical status, undergoing infra-umbilical surgeries were randomly allocated to one of the 4 intervention groups. All the 4 intervention groups received 0.5% bupivacaine (H) 3ml as a primary anesthetic agent. Group I and III received 50 IU and 100 IU salmon calcitonin as an adjuvant. Group II received placebo and group IV (control) received no adjuvant. Pinprick test, Bromage scale and 10-point Visual analog scale (VAS) were used to measure the efficacy.Results: All the study groups were comparable with respect to all baseline variables. The time interval to the first dose of analgesia was longest in 100 I.U. calcitonin group, followed by 50 I.U. calcitonin group, placebo control group. The mean duration of analgesia (in minutes) among group I (100I.U. calcitonin) was 230.00±92.39, 159.25±21.59 among group II (Placebo), 161.50±31.20 among group III (50 I.U. calcitonin) and 142.75±20.22 among group IV. Considering group IV (control group) as base line. The differences of duration of analgesia (in minutes) in group I, group II and group III with baseline value (group IV) were statistically significant (P value <0.05). Even though the proportion of subjects developing adverse events was slightly higher in 100 I.U calcitonin groups compared to other groups, they were minor adverse events and were managed appropriately. There were no significant differences across the study groups in terms of hemodynamic stability.Conclusions: Salmon calcitonin as adjuvant increases the duration of postoperative analgesia. Even though the there slightly higher incidence of adverse events with 100 I.U calcitonin they are minor and the risk-benefit ratio favors calcitonin use. To make a categorical recommendation on the appropriate dose, there is further need for large-scale studies and pooled analysis.

show abstract

Immunoreactive Calcitonin in Human Cerebrospinal Fluid∗*

Cited by 57 publications

References 19 publications

Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Adenohypophyseal Hormones in the CSF

Efficacy and safety of two different doses of intrathecal calcitonin, a randomized controlled study

Contact Info

Product

Resources

About